Overview

Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

Status:
Withdrawn
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
The long-term goal of this study is to learn if Zoledronic Acid can prevent or reduce pain in sickle cell disease. The goal of this study is to learn about the safety of Zoledronic Acid in persons with sickle cell disease who experience chronic pain requiring medical treatment or use of narcotics.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
Novartis
Treatments:
Diphosphonates
Zoledronic Acid